Shalini L Bhambani, MD
Cardiovascular Disease (Cardiology) · Redwood City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 5 carriers
- Offices
- 11
Offices
11 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center · Sequoia Hospital. That is not proof they admit you there this week.
Plans that list them
17 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bhambani’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A121068 · Current
Licensed to practise in California · since 2012 · expires 2028-02-29 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Sequoia HospitalRedwood City, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 104.12 (51.8 to 156.44) · 56 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sequoia Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 104.12 (51.8 to 156.44) · 56 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.98) · 472 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.58 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 258 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.5 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,231 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.01 to 0.44) · 3,018 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.44) · 3,164 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,402 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.47 (0.04 to 2.9) · 926 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.68 (0.21 to 3.16) · 1,310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.54 (4.42 to 14.67) · 978 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.98 (1.61 to 8.36) · 924 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 192 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.43) · 2,501 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 332 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.702 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 67 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 295 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -27.1 · 76 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.3 · 304 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.6 · 178 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 180 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 305 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 29 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.7) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 713 cases | No different | Jan 2024 – Dec 2024 |
What patients said (631 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
Original Medicare doctor bills
$380,100
Medicare paid this office $380,100 for 1,265 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 412 | $105,684 | $158 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 306 | $60,364 | $181 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 31 | $46,332 | $1,495 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 146 | $37,660 | $105 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 31 | $24,969 | $403 |
See all 35 services
| Long return visit (40+ min) | 412 | $105,684 | $158 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 306 | $60,364 | $181 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 31 | $46,332 | $1,495 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 146 | $37,660 | $105 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 31 | $24,969 | $403 |
| New patient visit (60+ min) | 63 | $12,162 | $193 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $10,900 | $149 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 44 | $9,644 | $219 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 437 | $7,481 | $13 |
| Return visit (30+ min) | 59 | $6,594 | $105 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 366 | $6,441 | $15 |
| Return visit (30+ min) | 53 | $4,577 | $85 |
| Long return visit (40+ min) | 30 | $3,488 | $113 |
| Ultrasound of heart with probe in esophagus, with report | 37 | $3,305 | $89 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 52 | $3,182 | $60 |
| Programming of dual lead pacemaker system | 21 | $2,853 | $75 |
| Ultrasound of heart with probe in esophagus during surgery on heart or great blood vessels with report | 14 | $2,733 | $195 |
| 3d radiographic procedure | 90 | $2,681 | $25 |
| Programming of multiple lead pacemaker system | 11 | $2,228 | $77 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 31 | $2,202 | $71 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 90 | $2,010 | $21 |
| External shock to heart to regulate heart beat | 18 | $1,935 | $97 |
| Hospital discharge day management, more than 30 minutes | 16 | $1,591 | $99 |
| Ultrasound of heart, follow-up | 12 | $1,522 | $95 |
| Evaluation of implantable heart and blood vessel monitoring system | 11 | $1,141 | $46 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,121 | $70 |
| Heart rhythm recording of continous external ekg over 8-15 days | 88 | $1,114 | $12 |
| Heart muscle strain imaging | 18 | $926 | $37 |
| Injection, regadenoson, 0.1 mg | 32 | $732 | None |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 31 | $633 | $20 |
| Ultrasound of heart blood flow, valves and chambers | 36 | $599 | $16 |
| Ultrasound of heart, follow-up | 19 | $463 | $22 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 31 | $387 | $12 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 18 | $119 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 40 | $115 | $3 |
Who their Medicare patients are
1,265 Original Medicare patients in 2024. Average age 78 · Under 65 1% · 85 and older 21% · Women 53% · Also on Medicaid 5% · Health risk score 1.18. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Atrial fibrillation 55% · Coronary heart disease 38% · Heart failure 26% · Diabetes 23% · Chronic kidney disease 22% · Cancer 17% · Depression 14% · COPD 11% · Stroke 9% · Dementia 8%.
The office billed $1,672,231, Medicare allowed $502,347 and paid $380,100; for 3,893 services of 57 kinds; $738 of it was for drugs given in the office and $379,362 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,265 | 3,893 | 78 | 1.18 | $1,672,231 | $380,100 |
| 2023 | 1,239 | 3,842 | 78 | 1.27 | $1,937,676 | $472,909 |
| 2022 | 1,137 | 3,648 | 78 | 1.23 | $1,665,548 | $421,528 |
| 2021 | 972 | 3,362 | 78 | 1.26 | $1,342,326 | $359,379 |
| 2020 | 693 | 3,544 | 78 | 1.58 | $1,216,201 | $321,843 |
| 2019 | 748 | 4,281 | 79 | 1.68 | $1,407,913 | $357,955 |
| 2018 | 1,067 | 7,828 | 79 | 1.59 | $1,269,884 | $327,145 |
| 2017 | 282 | 1,325 | 79 | 1.49 | $467,141 | $118,972 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 31 services
| Long return visit (40+ min) | 406 | $116,272 | $157 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 50 | $76,506 | $1,530 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 306 | $63,649 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 184 | $49,835 | $106 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 50 | $41,114 | $411 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 96 | $16,326 | $151 |
| New patient visit (60+ min) | 74 | $14,594 | $197 |
| Return visit (30+ min) | 81 | $10,453 | $111 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 39 | $9,025 | $231 |
| Injection, regadenoson, 0.1 mg | 49 | $7,463 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 109 | $6,823 | $61 |
| Return visit (30+ min) | 73 | $6,219 | $85 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 340 | $5,837 | $13 |
| Hospital discharge day management, more than 30 minutes | 53 | $5,782 | $105 |
| Programming of dual lead pacemaker system | 32 | $5,399 | $77 |
| Ultrasound of heart with probe in esophagus, with report | 39 | $3,775 | $94 |
| Long return visit (40+ min) | 29 | $3,384 | $117 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 41 | $2,863 | $70 |
| External shock to heart to regulate heart beat | 26 | $2,575 | $99 |
| Ultrasound of heart with probe in esophagus during surgery on heart or great blood vessels with report | 11 | $2,207 | $201 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 82 | $1,849 | $23 |
| 3d radiographic procedure | 64 | $1,633 | $25 |
| Heart rhythm recording of continous external ekg over 8-15 days | 82 | $1,017 | $12 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 48 | $1,002 | $20 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $711 | $30 |
| Ultrasound of heart blood flow, valves and chambers | 42 | $711 | $16 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 48 | $601 | $12 |
| Ultrasound of heart, follow-up | 23 | $587 | $23 |
| Heart muscle strain imaging | 11 | $508 | $39 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 42 | $124 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 17 | $122 | $6 |
2022: 28 services
| Long return visit (40+ min) | 328 | $98,438 | $159 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 40 | $63,625 | $1,552 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 219 | $44,887 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 175 | $42,413 | $92 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 40 | $34,283 | $418 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 123 | $23,447 | $172 |
| Return visit (30+ min) | 114 | $14,272 | $99 |
| New patient visit (60+ min) | 71 | $14,155 | $199 |
| Injection, regadenoson, 0.1 mg | 41 | $8,149 | None |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 37 | $7,989 | $216 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 110 | $6,994 | $61 |
| Return visit (30+ min) | 64 | $5,729 | $88 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 339 | $5,606 | $13 |
| Hospital discharge day management, more than 30 minutes | 55 | $5,605 | $93 |
| Ultrasound of heart with probe in esophagus, with report | 50 | $4,891 | $94 |
| External shock to heart to regulate heart beat | 41 | $4,359 | $97 |
| Programming of dual lead pacemaker system | 22 | $4,352 | $79 |
| Long return visit (40+ min) | 26 | $3,326 | $128 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $2,349 | $98 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 33 | $2,273 | $69 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 67 | $1,598 | $24 |
| 3d radiographic procedure | 48 | $1,206 | $23 |
| Heart rhythm recording of continous external ekg over 8-15 days | 67 | $985 | $14 |
| Ultrasound of heart blood flow, valves and chambers | 48 | $783 | $16 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 30 | $687 | $23 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 29 | $630 | $20 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 29 | $410 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 49 | $139 | $3 |
2021: 37 services
| Long return visit (40+ min) | 235 | $79,590 | $157 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 184 | $41,684 | $93 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 25 | $39,196 | $1,568 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 170 | $37,562 | $204 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 115 | $22,706 | $180 |
| Return visit (30+ min) | 122 | $21,159 | $114 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 25 | $20,575 | $420 |
| New patient visit (60+ min) | 50 | $10,401 | $208 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 136 | $8,876 | $63 |
| Hospital discharge day management, more than 30 minutes | 67 | $7,109 | $96 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 25 | $5,927 | $237 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 291 | $4,879 | $13 |
| Injection, regadenoson, 0.1 mg | 25 | $4,805 | None |
| Ultrasound of heart with probe in esophagus, with report | 45 | $4,532 | $96 |
| External shock to heart to regulate heart beat | 44 | $4,468 | $99 |
| Return visit (30+ min) | 47 | $4,261 | $91 |
| Telephone medical discussion with physician, 21-30 minutes | 21 | $3,886 | $90 |
| Emergency department visit with high level of medical decision making | 20 | $3,096 | $155 |
| Long return visit (40+ min) | 23 | $3,070 | $133 |
| New patient visit (45+ min) | 18 | $2,811 | $156 |
| Initial hospital care with same-day admission and discharge with high level of medical decision making, per day at least 85 minutes | 12 | $2,314 | $193 |
| Programming of dual lead pacemaker system | 15 | $2,313 | $75 |
| 3d radiographic procedure with computerized image postprocessing | 27 | $1,987 | $71 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 72 | $1,833 | $24 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 23 | $1,605 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,489 | $65 |
| Heart rhythm recording of continous external ekg over 8-15 days | 69 | $1,111 | $15 |
| Ultrasound of heart blood flow, valves and chambers | 48 | $809 | $16 |
| Short return visit (20+ min) | 11 | $674 | $61 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 24 | $563 | $23 |
| Ultrasound of heart, follow-up | 18 | $461 | $23 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 24 | $401 | $16 |
| 3d radiographic procedure | 15 | $342 | $23 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 27 | $333 | $6 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $253 | $23 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 51 | $149 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 13 | $92 | $7 |
2020: 34 services
| Long return visit (40+ min) | 197 | $49,670 | $131 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 28 | $46,785 | $1,613 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 174 | $44,611 | $96 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 152 | $32,471 | $199 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 28 | $24,221 | $418 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 113 | $22,624 | $185 |
| Return visit (30+ min) | 108 | $12,691 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 133 | $9,702 | $66 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 27 | $6,137 | $227 |
| New patient visit (60+ min) | 30 | $5,870 | $196 |
| Telephone medical discussion with physician, 21-30 minutes | 38 | $5,582 | $98 |
| Injection, regadenoson, 0.1 mg | 28 | $5,420 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 227 | $5,129 | $15 |
| External shock to heart to regulate heart beat | 41 | $4,416 | $103 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 254 | $3,958 | $6 |
| Hospital discharge day management, more than 30 minutes | 38 | $3,790 | $100 |
| Return visit (30+ min) | 49 | $3,639 | $73 |
| Long return visit (40+ min) | 30 | $3,182 | $103 |
| Ultrasound of heart with probe in esophagus, with report | 27 | $2,857 | $102 |
| Initial hospital observation care per day, typically 70 minutes | 16 | $2,702 | $169 |
| External ekg recording for more than 48 hours up to 21 days | 68 | $1,991 | $28 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 28 | $1,986 | $68 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 70 | $1,813 | $25 |
| New patient visit (45+ min) | 11 | $1,718 | $156 |
| Programming of dual lead pacemaker system | 13 | $1,593 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,587 | $66 |
| Emergency department visit with high level of medical decision making | 11 | $1,536 | $140 |
| Short return visit (20+ min) | 13 | $1,159 | $64 |
| Hospital observation care on day of discharge | 13 | $878 | $68 |
| Ultrasound of heart, follow-up | 19 | $670 | $24 |
| 3d radiographic procedure | 26 | $625 | $23 |
| Ultrasound of heart blood flow, valves and chambers | 27 | $480 | $17 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 17 | $163 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 27 | $84 | $3 |
2019: 36 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 248 | $61,167 | $92 |
| Long return visit (40+ min) | 208 | $52,605 | $127 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 34 | $51,311 | $1,509 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 158 | $32,753 | $179 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 34 | $27,762 | $408 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 106 | $23,551 | $200 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 182 | $12,703 | $66 |
| New patient visit (60+ min) | 52 | $8,941 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 62 | $7,532 | $64 |
| Return visit (30+ min) | 70 | $7,021 | $92 |
| Injection, regadenoson, 0.1 mg | 35 | $6,451 | None |
| Initial hospital observation care per day, typically 70 minutes | 37 | $6,242 | $164 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 344 | $5,596 | $6 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 208 | $5,176 | $15 |
| Hospital discharge day management, more than 30 minutes | 43 | $4,346 | $97 |
| External shock to heart to regulate heart beat | 39 | $4,233 | $98 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 19 | $4,140 | $218 |
| Emergency department visit with high level of medical decision making | 24 | $3,513 | $146 |
| Ultrasound of heart with probe in esophagus, with report | 33 | $3,501 | $97 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 36 | $2,428 | $67 |
| Hospital observation care on day of discharge | 31 | $2,039 | $66 |
| External ekg recording for more than 48 hours up to 21 days | 70 | $1,916 | $26 |
| Long return visit (40+ min) | 17 | $1,871 | $98 |
| Return visit (30+ min) | 25 | $1,749 | $70 |
| Programming of dual lead pacemaker system | 12 | $1,741 | $60 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 70 | $1,702 | $23 |
| 3d radiographic procedure | 47 | $1,165 | $22 |
| Ultrasound of heart blood flow, valves and chambers | 15 | $804 | $54 |
| Short return visit (20+ min) | 15 | $714 | $45 |
| Ultrasound of heart blood flow, valves and chambers | 37 | $657 | $16 |
| Ultrasound of heart, follow-up | 20 | $623 | $23 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 17 | $444 | $26 |
| Blood test, clotting time | 33 | $171 | $4 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $159 | $9 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 38 | $120 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 15 | $111 | $7 |
2018: 33 services
| Long return visit (40+ min) | 310 | $63,356 | $122 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 26 | $40,750 | $1,509 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 181 | $37,949 | $93 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 299 | $33,049 | $19 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 116 | $22,960 | $190 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 25 | $20,873 | $401 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 103 | $18,816 | $178 |
| Blood test, clotting time | 314 | $14,337 | $5 |
| New patient visit (60+ min) | 43 | $7,720 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 72 | $7,697 | $65 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 98 | $6,448 | $64 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 24 | $5,539 | $231 |
| Injection, regadenoson, 0.1 mg | 26 | $4,788 | None |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 261 | $3,671 | $6 |
| External shock to heart to regulate heart beat | 32 | $3,391 | $94 |
| Return visit (30+ min) | 37 | $3,251 | $86 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 131 | $3,188 | $16 |
| Initial hospital observation care per day, typically 70 minutes | 16 | $2,649 | $166 |
| Ultrasound of heart with probe in esophagus, with report | 24 | $2,634 | $98 |
| Programming of dual lead pacemaker system | 35 | $2,497 | $50 |
| Hospital discharge day management, more than 30 minutes | 19 | $2,005 | $95 |
| Emergency department visit with high level of medical decision making | 13 | $1,916 | $147 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 27 | $1,911 | $68 |
| External ekg recording for more than 48 hours up to 21 days | 53 | $1,413 | $26 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 52 | $1,227 | $23 |
| Ultrasound of heart blood flow, valves and chambers | 21 | $1,123 | $53 |
| Hospital observation care on day of discharge | 16 | $1,057 | $66 |
| Return visit (30+ min) | 15 | $1,048 | $70 |
| Short return visit (20+ min) | 16 | $730 | $46 |
| 3d radiographic procedure | 32 | $728 | $23 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 23 | $603 | $26 |
| Ultrasound of heart blood flow, valves and chambers | 26 | $479 | $17 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 26 | $83 | $3 |
2017: 27 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 14 | $20,691 | $1,478 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 95 | $16,926 | $93 |
| Long return visit (40+ min) | 67 | $11,396 | $134 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $9,198 | $180 |
| New patient visit (60+ min) | 37 | $6,966 | $188 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 29 | $6,758 | $233 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 14 | $6,428 | $230 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 22 | $6,050 | $275 |
| Critical care, first 30-74 minutes | 14 | $3,905 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $3,222 | $64 |
| Injection, regadenoson, 0.1 mg | 14 | $2,432 | None |
| External shock to heart to regulate heart beat | 20 | $2,104 | $100 |
| Hospital discharge day management, more than 30 minutes | 20 | $1,954 | $98 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 151 | $1,937 | $6 |
| 3d radiographic procedure with computerized image postprocessing | 27 | $1,864 | $69 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 31 | $1,781 | $57 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 64 | $1,223 | $16 |
| Ultrasound of heart blood flow, valves and chambers | 22 | $1,208 | $55 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,171 | $98 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 14 | $1,053 | $75 |
| External ekg recording for more than 48 hours up to 21 days | 23 | $649 | $28 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 22 | $589 | $27 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 23 | $560 | $24 |
| Short return visit (20+ min) | 12 | $545 | $45 |
| Ultrasound of heart blood flow, valves and chambers | 16 | $265 | $17 |
| 3d radiographic procedure | 11 | $253 | $23 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 17 | $49 | $3 |
Medicaid work
$756 in 2023
Medicaid paid $756 for 16 billed services this clinician did in 2023, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 16 | $756 |
| 2023 | 16 | 1 | 16 | $756 |
| 2021 | 63 | 1 | 16 | $1,852 |
| 2019 | 12 | 1 | 12 | $100 |
See the largest Medicaid services in earlier years
2021
| Long return visit (40+ min) | 63 | $1,852 |
2019
| Long return visit (40+ min) | 12 | $100 |
Drugs they prescribed that Part D paid
$762,879
Pharmacies billed $762,879 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,252) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
2,688 generic and 564 brand-name prescriptions · $762,879 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 260 | $380,827 | $1,465 |
| Xarelto | 85 | $110,767 | $1,303 |
| Repatha Sureclick | 59 | $74,882 | $1,269 |
| Jardiance | 48 | $64,571 | $1,345 |
| Entresto | 24 | $38,032 | $1,585 |
See all 39 drugs
| Eliquis | 260 | $380,827 | $1,465 |
| Xarelto | 85 | $110,767 | $1,303 |
| Repatha Sureclick | 59 | $74,882 | $1,269 |
| Jardiance | 48 | $64,571 | $1,345 |
| Entresto | 24 | $38,032 | $1,585 |
| Rosuvastatin | 260 | $4,989 | $19 |
| Atorvastatin | 362 | $4,352 | $12 |
| Metoprolol | 169 | $3,141 | $19 |
| Ezetimibe | 88 | $2,528 | $29 |
| Olmesartan Medoxomil | 127 | $2,503 | $20 |
| Losartan | 239 | $2,367 | $10 |
| Amlodipine Besylate | 237 | $2,276 | $10 |
| Valsartan | 67 | $2,201 | $33 |
| Diltiazem 24hr Er (Cd) | 50 | $1,875 | $37 |
| Carvedilol | 152 | $1,671 | $11 |
| Valsartan-Hydrochlorothiazide | 17 | $1,565 | $92 |
| Sotalol Af | 14 | $1,275 | $91 |
| Propranolol Hcl Er | 26 | $1,004 | $39 |
| Flecainide Acetate | 21 | $966 | $46 |
| Torsemide | 39 | $956 | $25 |
| Nebivolol | 12 | $767 | $64 |
| Clopidogrel | 33 | $729 | $22 |
| Propranolol | 33 | $716 | $22 |
| Potassium Chloride | 19 | $654 | $34 |
| Telmisartan | 11 | $616 | $56 |
| Spironolactone | 81 | $579 | $7 |
| Furosemide | 86 | $570 | $7 |
| Hydrochlorothiazide | 101 | $561 | $6 |
| Chlorthalidone | 37 | $527 | $14 |
| Lisinopril | 51 | $437 | $9 |
| Irbesartan | 22 | $355 | $16 |
| Hydralazine | 20 | $319 | $16 |
| Losartan-Hydrochlorothiazide | 12 | $316 | $26 |
| Warfarin | 14 | $275 | $20 |
| Atenolol | 12 | $263 | $22 |
| Clonidine | 16 | $222 | $14 |
| Levothyroxine | 14 | $206 | $15 |
| Diltiazem | 19 | $205 | $11 |
| Metoprolol | 39 | $136 | $3 |
Year by year
| 2024 | 3,252 | 443 | 0% (0) | 17% | $762,879 |
| 2023 | 2,954 | 407 | 0% (0) | None | $776,049 |
| 2022 | 2,042 | 308 | 0% (0) | None | $398,343 |
| 2021 | 1,655 | 251 | 0% (0) | None | $305,275 |
| 2020 | 1,282 | 204 | 0% (0) | 18% | $215,295 |
| 2019 | 1,444 | 355 | 0% (0) | 14% | $171,185 |
| 2018 | 1,654 | 431 | 0% (0) | 9% | $118,714 |
| 2017 | 100 | 46 | 0% (0) | 32% | $12,236 |
| 2016 | 141 | 40 | 0% (0) | 23% | $13,825 |
| 2015 | 156 | 36 | 0% (0) | 25% | $11,977 |
| 2014 | 100 | 23 | 0% (0) | None | $3,945 |
| 2013 | 88 | 22 | 0% (0) | 14% | $2,405 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 37 drugs
| Eliquis | 305 | $445,547 | $1,461 |
| Xarelto | 70 | $90,450 | $1,292 |
| Repatha Sureclick | 58 | $70,741 | $1,220 |
| Jardiance | 31 | $45,240 | $1,459 |
| Entresto | 22 | $37,269 | $1,694 |
| Praluent | 16 | $15,858 | $991 |
| Atorvastatin | 344 | $4,968 | $14 |
| Rosuvastatin | 175 | $4,536 | $26 |
| Metoprolol | 149 | $3,314 | $22 |
| Amlodipine Besylate | 227 | $2,842 | $13 |
| Olmesartan Medoxomil | 74 | $2,826 | $38 |
| Losartan | 187 | $2,778 | $15 |
| Flecainide Acetate | 39 | $2,434 | $62 |
| Carvedilol | 172 | $2,306 | $13 |
| Valsartan | 58 | $2,232 | $38 |
| Ezetimibe | 68 | $2,180 | $32 |
| Torsemide | 50 | $1,991 | $40 |
| Valsartan-Hydrochlorothiazide | 18 | $1,866 | $104 |
| Diltiazem 24hr Er (Cd) | 29 | $1,841 | $63 |
| Irbesartan | 25 | $1,530 | $61 |
| Sotalol Af | 13 | $1,358 | $104 |
| Potassium Chloride | 36 | $983 | $27 |
| Cilostazol | 11 | $873 | $79 |
| Chlorthalidone | 24 | $758 | $32 |
| Furosemide | 73 | $623 | $9 |
| Propranolol Hcl Er | 16 | $610 | $38 |
| Levothyroxine | 26 | $598 | $23 |
| Lisinopril | 73 | $513 | $7 |
| Spironolactone | 58 | $512 | $9 |
| Clopidogrel | 29 | $391 | $13 |
| Hydrochlorothiazide | 92 | $383 | $4 |
| Metoprolol | 57 | $371 | $7 |
| Hydralazine | 25 | $330 | $13 |
| Cartia Xt | 20 | $282 | $14 |
| Warfarin | 11 | $276 | $25 |
| Gabapentin | 14 | $214 | $15 |
| Amoxicillin | 11 | $25 | $2 |
2022: 31 drugs
| Eliquis | 188 | $242,748 | $1,291 |
| Xarelto | 53 | $52,264 | $986 |
| Repatha Sureclick | 34 | $26,399 | $776 |
| Brilinta | 12 | $4,917 | $410 |
| Rosuvastatin | 78 | $3,683 | $47 |
| Atorvastatin | 255 | $3,555 | $14 |
| Metoprolol | 122 | $2,472 | $20 |
| Ezetimibe | 33 | $1,999 | $61 |
| Valsartan | 50 | $1,715 | $34 |
| Amlodipine Besylate | 161 | $1,673 | $10 |
| Losartan | 160 | $1,616 | $10 |
| Flecainide Acetate | 17 | $1,508 | $89 |
| Carvedilol | 122 | $1,479 | $12 |
| Torsemide | 38 | $1,250 | $33 |
| Diltiazem 24hr Er (Cd) | 28 | $1,240 | $44 |
| Clonidine | 15 | $1,225 | $82 |
| Irbesartan | 17 | $996 | $59 |
| Valsartan-Hydrochlorothiazide | 12 | $991 | $83 |
| Cilostazol | 13 | $853 | $66 |
| Hydralazine | 36 | $553 | $15 |
| Lisinopril | 75 | $537 | $7 |
| Spironolactone | 36 | $443 | $12 |
| Metoprolol | 47 | $430 | $9 |
| Clopidogrel | 20 | $427 | $21 |
| Levothyroxine | 16 | $398 | $25 |
| Amiodarone | 15 | $395 | $26 |
| Potassium Chloride | 15 | $386 | $26 |
| Furosemide | 59 | $346 | $6 |
| Hydrochlorothiazide | 76 | $278 | $4 |
| Olmesartan Medoxomil | 16 | $115 | $7 |
| Warfarin | 12 | $95 | $8 |
2021: 28 drugs
| Eliquis | 182 | $208,616 | $1,146 |
| Xarelto | 30 | $36,132 | $1,204 |
| Repatha Sureclick | 15 | $8,437 | $562 |
| Atorvastatin | 197 | $3,814 | $19 |
| Rosuvastatin | 59 | $2,938 | $50 |
| Metoprolol | 108 | $2,437 | $23 |
| Ezetimibe | 26 | $1,664 | $64 |
| Losartan | 114 | $1,592 | $14 |
| Amlodipine Besylate | 145 | $1,466 | $10 |
| Valsartan | 36 | $1,321 | $37 |
| Carvedilol | 100 | $1,198 | $12 |
| Torsemide | 37 | $964 | $26 |
| Flecainide Acetate | 12 | $947 | $79 |
| Valsartan-Hydrochlorothiazide | 13 | $837 | $64 |
| Amiodarone | 14 | $722 | $52 |
| Irbesartan | 15 | $679 | $45 |
| Lisinopril | 72 | $657 | $9 |
| Diltiazem 24hr Er (Cd) | 15 | $590 | $39 |
| Metoprolol | 41 | $563 | $14 |
| Nitroglycerin | 14 | $315 | $22 |
| Hydrochlorothiazide | 72 | $304 | $4 |
| Clopidogrel | 16 | $282 | $18 |
| Hydralazine | 19 | $275 | $14 |
| Spironolactone | 21 | $265 | $13 |
| Warfarin | 13 | $256 | $20 |
| Furosemide | 31 | $177 | $6 |
| Pantoprazole | 13 | $167 | $13 |
| Omeprazole | 13 | $82 | $6 |
2020: 25 drugs
| Eliquis | 164 | $158,244 | $965 |
| Xarelto | 14 | $12,701 | $907 |
| Dofetilide | 16 | $4,793 | $300 |
| Atorvastatin | 163 | $3,403 | $21 |
| Rosuvastatin | 51 | $3,271 | $64 |
| Prasugrel | 11 | $2,262 | $206 |
| Metoprolol | 64 | $2,018 | $32 |
| Losartan | 111 | $1,744 | $16 |
| Ezetimibe | 14 | $902 | $64 |
| Amlodipine Besylate | 120 | $893 | $7 |
| Torsemide | 25 | $772 | $31 |
| Lisinopril | 83 | $746 | $9 |
| Diltiazem 24hr Er (Cd) | 11 | $642 | $58 |
| Irbesartan | 18 | $638 | $35 |
| Carvedilol | 68 | $575 | $8 |
| Potassium Chloride | 12 | $480 | $40 |
| Hydralazine | 13 | $397 | $31 |
| Metoprolol | 17 | $379 | $22 |
| Spironolactone | 28 | $281 | $10 |
| Hydrochlorothiazide | 34 | $230 | $7 |
| Warfarin | 17 | $193 | $11 |
| Clopidogrel | 13 | $173 | $13 |
| Furosemide | 29 | $139 | $5 |
| Pantoprazole | 17 | $132 | $8 |
| Sotalol | 12 | $102 | $9 |
2019: 22 drugs
| Eliquis | 132 | $106,536 | $807 |
| Warfarin | 309 | $7,107 | $23 |
| Dofetilide | 13 | $6,579 | $506 |
| Atorvastatin | 136 | $3,463 | $25 |
| Metoprolol | 94 | $2,973 | $32 |
| Rosuvastatin | 16 | $1,083 | $68 |
| Amlodipine Besylate | 103 | $1,073 | $10 |
| Losartan | 78 | $1,044 | $13 |
| Ezetimibe | 11 | $878 | $80 |
| Irbesartan | 13 | $866 | $67 |
| Flecainide Acetate | 11 | $801 | $73 |
| Lisinopril | 71 | $626 | $9 |
| Carvedilol | 49 | $512 | $10 |
| Bumetanide | 11 | $463 | $42 |
| Clopidogrel | 13 | $420 | $32 |
| Torsemide | 23 | $331 | $14 |
| Spironolactone | 37 | $272 | $7 |
| Jantoven | 18 | $237 | $13 |
| Hydrochlorothiazide | 26 | $227 | $9 |
| Metoprolol | 25 | $134 | $5 |
| Pantoprazole | 13 | $124 | $10 |
| Furosemide | 34 | $110 | $3 |
2018: 24 drugs
| Eliquis | 75 | $51,421 | $686 |
| Warfarin | 708 | $14,661 | $21 |
| Enoxaparin | 58 | $11,560 | $199 |
| Coumadin | 16 | $3,326 | $208 |
| Atorvastatin | 69 | $2,114 | $31 |
| Metoprolol | 62 | $1,798 | $29 |
| Ezetimibe | 11 | $1,659 | $151 |
| Valsartan | 18 | $909 | $50 |
| Flecainide Acetate | 13 | $856 | $66 |
| Jantoven | 47 | $756 | $16 |
| Sotalol Af | 13 | $728 | $56 |
| Losartan | 38 | $576 | $15 |
| Lisinopril | 56 | $508 | $9 |
| Amlodipine Besylate | 82 | $500 | $6 |
| Irbesartan | 11 | $494 | $45 |
| Torsemide | 33 | $290 | $9 |
| Cartia Xt | 13 | $263 | $20 |
| Carvedilol | 30 | $262 | $9 |
| Hydrochlorothiazide | 36 | $235 | $7 |
| Clopidogrel | 12 | $211 | $18 |
| Spironolactone | 21 | $196 | $9 |
| Furosemide | 42 | $179 | $4 |
| Amiodarone | 11 | $158 | $14 |
| Metoprolol | 23 | $127 | $6 |
2017: 3 drugs
| Eliquis | 16 | $8,538 | $534 |
| Atorvastatin | 12 | $309 | $26 |
| Metoprolol | 12 | $216 | $18 |
2016: 2 drugs
| Atorvastatin | 36 | $566 | $16 |
| Metoprolol | 11 | $291 | $26 |
2015: 4 drugs
| Eliquis | 15 | $5,746 | $383 |
| Metoprolol | 13 | $489 | $38 |
| Atorvastatin | 18 | $281 | $16 |
| Metoprolol | 12 | $23 | $2 |
2014: 2 drugs
| Atorvastatin | 12 | $106 | $9 |
| Furosemide | 13 | $49 | $4 |
Money from drug and device companies
$585 in 2025
| 2025 | 4 | 6 | None | $585 |
| 2024 | 3 | 6 | None | $823 |
| 2023 | 3 | 4 | None | $489 |
| 2022 | 1 | 2 | None | $379 |
| 2021 | 1 | 1 | None | $37 |
| 2020 | 6 | 7 | None | $164 |
| 2019 | 13 | 55 | None | $1,203 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AtriCure | Epi-Sense Guided Coagulation System With Visitrax | $269 | 2 payments
|
| Medtronic | Aurora Ev-Icd Mri Surescan | $164 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $137 | 2 payments
|
| Scpharmaceuticals | Furoscix | $15 | 1 payment
|
See all 6 published payments
| AtriCure | Meals · 2025-07-23 | Epi-Sense Guided Coagulation System With Visitrax | $164 |
| Scpharmaceuticals | Meals · 2025-06-19 | Furoscix | $15 |
| AtriCure | Meals · 2025-05-27 | Epi-Sense Guided Coagulation System With Visitrax | $106 |
| Medtronic | Meals · 2025-05-19 | Aurora Ev-Icd Mri Surescan | $164 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-01 | Camzyos | $131 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-17 | Camzyos | $6 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $823
| Boston Scientific | Rhythmia Mapping System | $526 | 4 payments
|
| Impulse Dynamics (USA) | Optimizer | $162 | 1 payment
|
| Kestra Medical Technology Services | Assure Wcd | $135 | 1 payment
|
2023: $489
| Ablacon | None | $241 | 1 payment
|
| Impulse Dynamics (USA) | Optimizer | $224 | 2 payments
|
| Boston Scientific | Watchman Access System | $24 | 1 payment
|
2022: $379
| Impulse Dynamics (USA) | Optimizer | $379 | 2 payments
|
2021: $37
| Abbott Laboratories | Ensite Precision Cardiac Mapping System | $37 | 1 payment
|
2020: $164
| Pfizer | Eliquis | $58 | 2 payments
|
| Abbott Laboratories | Fortify Assura, Ellipse Icd | $26 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $22 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $20 | 1 payment
|
| Amgen | Corlanor | $19 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $19 | 1 payment
|
2019: $1,203
| Amgen | Corlanor | $361 | 12 payments
|
| Boehringer Ingelheim Pharmaceuticals | Pradaxa | $138 | 10 payments
|
| Pfizer | Eliquis | $115 | 8 payments
|
| Novartis Pharmaceuticals | Entresto | $108 | 5 payments
|
| Sanofi-Aventis U.S. | Praluent | $101 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $93 | 4 payments
|
| Regeneron Healthcare Solutions | Praluent | $70 | 3 payments
|
| Biotronik | None | $62 | 1 payment
|
| Lundbeck | Northera | $49 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $38 | 2 payments
|
| Braemar Manufacturing | Cardiac Monitoring Suite | $29 | 1 payment
|
| Abbott Laboratories | Confirm Rx | $23 | 1 payment
|
| Daiichi Sankyo | Injectafer | $16 | 1 payment
|
Professional record
- NPI
- 1558635474
- Licence
- CA A121068California A121068: Current · expires 2028-02-29
- Trained
- Harvard Medical School, 2010
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Federal specialty code 207UN0901X (207UN0901X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2012-02-24
- NPI last updated
- 2020-06-02
- NPI record certified
- 2020-06-02
This is when the NPI record was last certified, not a medical board exam.